L1 cell adhesion molecule (L1CAM) in stage IB cervical cancer: distinct expression in squamous cell carcinomas and adenocarcinomas

Imagem de Miniatura
Arquivos
art_CARVALHO_L1_cell_adhesion_molecule_L1CAM_in_stage_IB_2020.PDF.pdf (451.58 KB)
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMJ PUBLISHING GROUP
Autores
Citação
JOURNAL OF CLINICAL PATHOLOGY, v.73, n.11, p.748-753, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aims L1 cell adhesion molecule (L1CAM) has been shown to be correlated with tumour progression, attributed to its possible association with epithelial-mesenchymal transition (EMT), characterised by the expression of vimentin and loss of e-cadherin. Herein, we investigate the associations between L1CAM and clinicopathological parameters, as well as the expression of vimentin and e-cadherin, in carcinomas restricted to the cervix. Methods The study was retrospective observational and included 45 squamous cell carcinomas (63.4%) and 26 adenocarcinomas (36.6%) submitted to primary surgical treatment. Patient age, FIGO (International Federation of Gynecology and Obstetrics) stage, tumour size and follow-up were obtained from the medical records. All the slides were revised to evaluate histological differentiation, lymphovascular space invasion, depth of infiltration, disease-free cervical wall thickness, pattern of invasion front, Silva pattern (for adenocarcinomas) and the percentage of tumour-infiltrating lymphocytes. Tissue microarrays were constructed for immunohistochemical staining for L1CAM, e-cadherin and vimentin. Results Adenocarcinomas were associated with lower disease-free and overall survival. L1CAM and vimentin expressions were more frequent among adenocarcinomas, although loss of e-cadherin expression was more common among squamous carcinomas. L1CAM expression was associated with larger tumours, vimentin expression and lower disease-free survival. No association was observed between the expression of either L1CAM or vimentin and loss of e-cadherin. High levels of tumour-infiltrating lymphocytes were more frequent in squamous cell carcinoma, high-grade tumours, destructive pattern at front of invasion and loss of e-cadherin expression. Conclusions Our results confirm the prognostic role of L1CAM in cervical carcinomas, but suggest a role for mechanisms other than EMT.
Palavras-chave
cervix uteri, uterine cervical neoplasms, immunohistochemistry, pathology, molecular, pathology, surgical
URI
https://observatorio.fm.usp.br/handle/OPI/38467
Referências
  1. Banister CE, 2017, ONCOTARGET, V8, P13375, DOI 10.18632/oncotarget.14533
  2. Bhatla N, 2019, INT J GYNECOL OBSTET, V145, P129, DOI 10.1002/ijgo.12749
  3. Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386
  4. Chen JL, 2018, EXP THER MED, V15, P2792, DOI 10.3892/etm.2018.5747
  5. Chen T, 2017, J CELL PHYSIOL, V232, P3261, DOI 10.1002/jcp.25797
  6. Cheng Y, 2012, HUM PATHOL, V43, P1213, DOI 10.1016/j.humpath.2011.08.025
  7. De Vivar AD, 2013, INT J GYNECOL PATHOL, V32, P592, DOI 10.1097/PGP.0b013e31829952c6
  8. Estimativa, 2018, INC CANC BRAS
  9. GLOBOCAN, 2018, INC MORT PREV CANC S
  10. Grage-Griebenow E, 2014, MOL ONCOL, V8, P982, DOI 10.1016/j.molonc.2014.03.001
  11. Huszar M, 2010, J PATHOL, V220, P551, DOI 10.1002/path.2673
  12. Ichikawa T, 2019, BRIT J CANCER, V121, P1058, DOI 10.1038/s41416-019-0646-8
  13. Jiang J, 2019, ONCOL LETT, V17, P5729, DOI 10.3892/ol.2019.10266
  14. Kiefel H, 2012, CELL ADHES MIGR, V6, P374, DOI 10.4161/cam.20832
  15. Klat J, 2019, ANTICANCER RES, V39, P421, DOI 10.21873/anticanres.13128
  16. Kurman RJ CM, 2014, WHO CLASSIFICATION T
  17. Liu LK, 2010, MODERN PATHOL, V23, P213, DOI 10.1038/modpathol.2009.160
  18. Lu W, 2019, DEV CELL, V49, P361, DOI 10.1016/j.devcel.2019.04.010
  19. Peng JF, 2016, FUTURE ONCOL, V12, P715, DOI 10.2217/fon.15.332
  20. Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450
  21. Schrevel M, 2017, ONCOTARGET, V8, P87568, DOI 10.18632/oncotarget.20976
  22. Sedlis A, 1999, GYNECOL ONCOL, V73, P177, DOI 10.1006/gyno.1999.5387
  23. Shtutman M, 2006, CANCER RES, V66, P11370, DOI 10.1158/0008-5472.CAN-06-2106
  24. Stewart CJR, 2011, HISTOPATHOLOGY, V58, P720, DOI 10.1111/j.1365-2559.2011.03787.x
  25. Stolnicu S, 2018, AM J SURG PATHOL, V42, P214, DOI 10.1097/PAS.0000000000000986
  26. Tampakis A, 2020, ACTA ONCOL, V59, P55, DOI 10.1080/0284186X.2019.1667022
  27. Tischler V, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-127
  28. van der Maten M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174180
  29. Versluis MAC, 2018, VIRCHOWS ARCH, V473, P591, DOI 10.1007/s00428-018-2444-8

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - LIM/58
Carregar mais